Quercetin (standalone)
KWER-se-tin
IUPAC 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
D+
34.5/100
Evidence Summary
Quercetin as a standalone supplement has weak evidence for longevity. Its primary interest is as the 'Q' in D+Q senolytic therapy, but without dasatinib, quercetin alone has not demonstrated meaningful senolytic activity in humans.
As a general anti-inflammatory flavonoid, quercetin has modest evidence for reducing blood pressure and improving endothelial function, but these are standard supplement-grade effects, not longevity-specific outcomes.
As a general anti-inflammatory flavonoid, quercetin has modest evidence for reducing blood pressure and improving endothelial function, but these are standard supplement-grade effects, not longevity-specific outcomes.
Safety Considerations
Generally well-tolerated as a dietary flavonoid. Low bioavailability. Potential CYP enzyme interactions. Not equivalent to D+Q senolytic protocol when taken alone.
Evidence Signals (0)
Known Interactions (1)
Products Containing Quercetin (standalone)
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.